Impact of Rapid Detection of MRSA
| Status: | Withdrawn |
|---|---|
| Conditions: | Hospital |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/15/2018 |
| Start Date: | January 2014 |
| End Date: | July 2016 |
Clinical and Economic Impact of a Rapid Test for Detection of Methicillin-resistant Staphylococcus Aureus (MRSA) From Sterile Sites (the Alere™ PBP2a)
The objective of this study is to evaluate the impact of the Alere™ PBP2a test combined
with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in
hospitalized patients with sterile site S. aureus infection.
with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in
hospitalized patients with sterile site S. aureus infection.
Inclusion criteria:
1. Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S.
aureus cultures (both control and intervention periods)
2. Above, with rapid PBP2a testing (intervention period only).
Exclusion criteria:
1. Patients with polymicrobial cultures (i.e., growth of S. aureus plus other organisms
in the culture).
2. Patients who have not provided MN authorization to use their medical records for
research.
3. Patients who have had the FilmArray Blood culture identification diagnostic test
performed on an index S. aureus blood culture.
4. Patients who have had a sterile source S. aureus culture within the prior 30 days.
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Ritu Banerjee, MD, Ph.D
Phone: 507-255-8464
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
